“Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer” (2021) Onkologija, 25(2), pp. 48–53. doi:10.25670/oi2021-017on.